Will the UK be the first European country to embrace psilocybin-assisted therapy?
At Prime Minister’s Questions, Boris Johnson responded to Tory MP Crispin Blunt’s call to reschedule psilocybin. Johnson told the house that he would consider ‘recent advice on reducing barriers to research with controlled drugs’, in a statement that galvanised the country’s biosciences industry.
Advocates hope the UK could soon move psilocybin, and other compounds, to Schedule 2 to reflect mounting evidence on their therapeutic potential. This would facilitate greater medical research, laying the foundations for a domestic market with direct access to London’s capital markets.Read More